Fertility Testing Before IVF: What Your Workup Should Actually Cover

If you have been told to “just start IVF” after one AMH result and a quick scan, it is reasonable to ask what else should be checked. Fertility testing before IVF should not be a minimal box-ticking exercise, and it should not become a shopping list of expensive add-ons either. The right workup is targeted. It should find treatable problems, estimate how the ovaries may respond to stimulation, check whether sperm or uterine factors change the plan, and avoid tests that do not improve real outcomes.

That approach is very much in line with the ASRM committee opinion on fertility evaluation, which recommends a systematic, expeditious evaluation of both partners, starting with the least invasive methods that detect common causes. So the real question is not, “What is the biggest panel I can order before IVF?” It is, “What information will actually change treatment or improve safety?”

What a useful pre-IVF workup should answer

A clinically meaningful pre-IVF evaluation should answer five questions:

1. Is ovulation happening, and is an endocrine disorder involved?
2. What is the likely ovarian response to stimulation?
3. Is there uterine or tubal disease that could reduce implantation or make embryo transfer unsafe?
4. Is there a male-factor reason to use IVF, or to use ICSI within IVF?
5. Are there genetic, infectious, metabolic, or medication-related issues relevant to treatment or pregnancy?

The sequence is not identical for every couple. Age, cycle pattern, prior surgery, pelvic infection, ectopic pregnancy, recurrent pregnancy loss, endometriosis, and previous IVF outcomes all matter. A 29-year-old with irregular cycles and acne does not need the exact same workup as a 40-year-old with regular cycles and two failed transfers.

Ovarian reserve, useful for planning stimulation, easy to overinterpret

AMH and antral follicle count, or AFC, are the most useful routine tests for predicting how the ovaries may respond to IVF stimulation. The updated ESHRE ovarian stimulation guideline recommends using either AMH or AFC to predict low or high ovarian response in IVF and ICSI cycles.

Here is what they do well:

• AMH can usually be measured at any point in the menstrual cycle. Hormonal contraception can temporarily lower AMH (and AFC), so a low result while on the pill may underestimate your reserve.
• AFC is counted on transvaginal ultrasound, usually in the early follicular phase.
• Low values suggest a higher chance of retrieving relatively few eggs.
• High values suggest a stronger response and, in some cases, a higher risk of ovarian hyperstimulation syndrome.

Here is what they do not do well:

• They do not directly measure egg quality.
• They do not tell you whether an embryo will be chromosomally normal.
• They are weak predictors of live birth on their own; age matters more.
• They do not tell you that natural conception is impossible.

This point matters because patients are often frightened by low AMH. The current NICE fertility guideline specifically advises against using AMH to predict the chance of pregnancy through spontaneous conception. In other words, AMH is mainly a stimulation-planning tool, not a complete fertility verdict.

A high AMH can be misunderstood too. It may be seen in people with polycystic ovarian morphology, and it often predicts a robust response to medication, but it does not guarantee healthy embryos or a baby. Age still remains a major driver of aneuploidy risk and IVF prognosis.

Older markers such as basal FSH and estradiol can still appear in charts, but they have limitations. If they are used, ASRM advises measuring them together on cycle days 2 to 4. Even then, a normal FSH does not rule out diminished ovarian reserve, and an elevated FSH does not prove pregnancy is out of reach. When AMH or AFC is available, they are generally more useful for planning stimulation.

Ovulation and endocrine testing should follow the clinical story

A good fertility workup does not confuse anovulation with diminished ovarian reserve. Those are different biological problems, and they lead to different treatment strategies.

Menstrual history is often the fastest starting point. According to ASRM guidance, cycles that occur about every 21 to 35 days usually suggest ovulation, although they do not prove it every month.

Testing should be directed by symptoms and cycle pattern:

• Progesterone can help confirm recent ovulation when timed correctly, but a single result is not a reliable test of “luteal phase quality.”
• TSH is commonly checked as part of the initial evaluation, because it is inexpensive and untreated thyroid disease affects both fertility and pregnancy. Guidelines (ASRM 2024, NICE) do not call for testing everyone, but reserve it for women with symptoms or higher risk, such as autoimmune disease, a personal or family history of thyroid disease, or a goitre.
• Prolactin is most appropriate when there is galactorrhea, irregular or absent periods, or suspected pituitary disease.
• FSH, LH, and estradiol are more relevant in amenorrhea, oligomenorrhea, suspected hypothalamic or pituitary dysfunction, or possible primary ovarian insufficiency.
• Androgen testing becomes important with hirsutism, acne, virilization, or suspected PCOS.

This matters before IVF because some women are pushed toward treatment without anyone fully mapping why ovulation is disturbed in the first place. If you have already been through confusion, irregular cycles, or failed treatment and want a clearer starting point, the Smart Fertility Score is a ten-minute self-assessment that highlights which areas are worth discussing with your fertility team.

Semen analysis, the half of the workup that gets underplayed

One of the most common pre-IVF mistakes is acting as if infertility lives only in the woman’s chart. It does not. Male factors contribute fully or partly in a substantial share of infertility cases, which is why ASRM recommends assessing both partners from the start.

A semen analysis should usually be part of the initial evaluation, not something postponed until later. The current AUA and ASRM male infertility guideline also stresses that the test should be interpreted alongside a reproductive and medical history.

A standard semen analysis typically looks at:

• semen volume
• sperm concentration
• total sperm number
• motility
• morphology
• leukocytes or other abnormalities

One abnormal sample is not automatically a diagnosis. Semen parameters vary naturally and can be affected by recent fever, abstinence interval, collection issues, and lab technique. Repeating the test is often appropriate when the first result is clearly abnormal.

The WHO laboratory manual for semen testing standardized analysis methods, but its reference limits are not a bright line between fertile and infertile men. A man can have values below a reference threshold and still conceive. He can also have “normal” values and still be part of the infertility picture.

Additional male testing is more useful when there is azoospermia, very low sperm concentration, suspected obstruction, abnormal exam findings, past chemotherapy or radiation, or previous testicular or reproductive surgery. In selected severe cases, genetic testing such as karyotype or Y chromosome microdeletion analysis may change counseling and management.

One test that is often marketed more aggressively than the evidence supports is sperm DNA fragmentation. The AUA and ASRM guidance does not recommend it as a routine first-line infertility test. It may have a role in selected situations, such as recurrent pregnancy loss or repeated unexplained IVF failure, but it is not a standard screening test for everyone.

Ultrasound is the baseline, not always the whole uterine evaluation

A transvaginal ultrasound is essential, but it is only the beginning of uterine assessment. It can evaluate uterine size, fibroids, endometrial appearance, adenomyosis features, endometriomas, ovarian morphology, AFC, and sometimes hydrosalpinx or other pelvic abnormalities.

What it may miss are smaller intracavitary lesions, such as:

• endometrial polyps
• submucosal fibroids
• adhesions
• some congenital uterine anomalies

That is where more targeted cavity testing may matter. The NICE fertility guideline and related evidence reviews support using additional imaging, such as saline-infusion sonography, when the history, bleeding pattern, ultrasound, or prior IVF outcomes raise suspicion. Hysteroscopy gives direct visualization and can treat certain findings, but it is invasive and not automatically necessary before a first IVF cycle in every asymptomatic patient.

The same caution applies to endometrial thickness. A thin lining can be clinically relevant and may justify a closer look for adhesions, hormonal issues, uterine pathology, or even measurement inconsistency. But thickness alone is an imperfect marker. It is not a complete test of receptivity, and there is no universally reliable fix for every thin-lining situation.

Tubal disease still matters before IVF

Many people assume tubal testing becomes irrelevant once IVF is planned because IVF bypasses the fallopian tubes for fertilization. That is only partly true.

The most important exception is hydrosalpinx, a damaged fluid-filled tube. Untreated hydrosalpinx can reduce IVF success, and treating it with salpingectomy or proximal tubal occlusion before IVF can improve outcomes in appropriately selected patients, according to the broader evidence summarized in the NICE fertility guideline.

This is why tubal assessment may still be important if there is a history of:

• pelvic inflammatory disease
• ectopic pregnancy
• tubal surgery
• endometriosis
• abnormal pelvic imaging
• suspected hydrosalpinx

Hysterosalpingography and hysterosalpingo-contrast sonography can be useful, depending on the situation. Diagnostic laparoscopy, however, is invasive and should not be used as a routine screening test without a specific reason.

Endometriosis and pelvic disease require judgment, not reflex surgery

Endometriosis can be easy to underestimate in IVF planning. Clues include severe period pain, deep dyspareunia, chronic pelvic pain, infertility, endometriomas, or suggestive imaging. A normal ultrasound does not exclude superficial disease.

But routine diagnostic laparoscopy for every IVF patient is not supported by the evidence. The decision should balance symptoms, imaging, age, ovarian reserve, previous surgery, pain severity, and time pressure. This is especially important with endometriomas, because surgery can remove healthy ovarian tissue along with the cyst wall and reduce ovarian reserve.

Before IVF, the key question is not “Should every endometriosis patient have surgery?” It is “Will surgery solve a problem that is likely to improve outcome enough to justify the delay and the risk to ovarian tissue?”

Genetic, infectious, and pregnancy-preparation screening

Genetic testing before IVF should be targeted, not indiscriminate. Useful triggers for counseling or testing include:

• family history of genetic disease
• hemoglobinopathies such as thalassemia and sickle cell disease, in either partner
• consanguinity (partners who are blood relatives), which raises the chance that both carry the same recessive condition
• other ancestry-associated carrier risks
• recurrent pregnancy loss
• severe male-factor infertility
• a previous affected pregnancy or child
• a known chromosomal rearrangement in either partner

Carrier screening can identify increased risk for certain recessive or X-linked conditions, but no panel detects everything. Parental karyotyping is not a routine test for every IVF patient. It becomes more relevant in recurrent pregnancy loss, prior chromosomal problems, or selected severe male-factor cases.

It is also worth being clear about PGT-A. It is not a universal fertility test, and it does not guarantee implantation or live birth. It assesses chromosome copy number in biopsied embryo cells, not every possible genetic issue. Whether it improves cumulative live birth for all IVF patients remains a debated question, influenced by age, embryo number, lab quality, and what embryos are available for transfer.

Then there is the basic safety workup that patients sometimes underestimate. NICE recommends offering testing for HIV, hepatitis B, and hepatitis C to people undergoing IVF. Medication review, supplement review, blood pressure, metabolic risk, vaccination status, and folic acid planning may not look glamorous on a fertility checklist, but they can prevent delays and lower pregnancy risk.

Tests that sound advanced, but often do not change outcomes

One of the biggest myths in fertility care is that more testing always means better care. It does not. A test is only useful if the result changes management in a way that improves safety or patient-important outcomes, ideally live birth.

Common pre-IVF add-ons that often lack strong evidence for routine use include:

• inhibin B for ovarian reserve assessment
• clomiphene challenge testing
• routine immune panels or natural killer cell testing
• endometrial receptivity assays in unselected patients
• routine reproductive-tract microbiome testing
• routine thrombophilia testing without a clear indication
• routine sperm DNA fragmentation testing in the initial evaluation

That does not mean these tests are never used. It means they should not be sold as default steps for everyone starting IVF.

A practical pre-IVF checklist to take to your clinic

If you want to know whether your fertility testing before IVF has been thorough enough, ask whether these points have been clearly documented:

1. Both partners were evaluated, not just one partner.
2. A semen analysis was done and properly interpreted, with repeat testing if the first result was significantly abnormal.
3. AMH or AFC was reviewed to plan stimulation dose and response risk, not to give you a simplistic fertility score.
4. Ovulation and endocrine questions were addressed if your cycles are irregular, absent, or suggestive of thyroid, prolactin, or androgen problems.
5. A transvaginal ultrasound assessed the uterus and ovaries carefully, including fibroids, adenomyosis features, endometriomas, and possible hydrosalpinx.
6. The uterine cavity was examined further only if indicated, such as abnormal bleeding, suspicious ultrasound findings, or prior failed transfers.
7. Tubal disease was considered, especially if you have a history of PID, ectopic pregnancy, surgery, or imaging concerns.
8. Genetic counseling or testing was offered selectively, based on family history, recurrent pregnancy loss, severe male factor, or prior affected pregnancy.
9. Infectious screening and preconception review were completed, including medication review and pregnancy safety planning.
10. Any proposed add-on was explained in terms of live birth or safety, not just because it produces another lab value.

The takeaway is simple. A strong pre-IVF workup is not the longest list of tests. It is the most targeted one. It should answer the right questions about ovulation, ovarian response, sperm, uterus, tubes, genetics, and pregnancy safety, while refusing the noise of tests that do not improve decisions.

If you want a clearer sense of which areas to raise with your fertility team before another cycle, start with the Smart Fertility Score.

Sources

• American Society for Reproductive Medicine (2021): Committee opinion on fertility evaluation of infertile women
• Human Reproduction: ESHRE guideline on ovarian stimulation and prediction of ovarian response in IVF/ICSI
• NICE: Fertility problems—assessment and treatment guideline
• American Urological Association and American Society for Reproductive Medicine: Male infertility guideline and interpretation of semen analysis
• World Health Organization: Laboratory manual for semen examination and processing

---

Follow Maha Hommos for daily evidence-based guidance: Instagram · YouTube · LinkedIn